UBS analyst David Vogt maintains NetApp (NASDAQ:NTAP) with a Neutral and lowers the price target from $91 to $78.
As Drugs Like Ozempic And Mounjaro Disrupt The Weigh Loss Market, Who Stands To Win — And Who Stands To Lose?
Ozempic, Wegovy and Mounjaro could very well have become the most sought-after weight-loss drugs of the past two…